HCPCS Level IIdrugActive
J3399
Inj onase abepar-xioi treat
BETOS: O1E
Effective: 2024-01-01
Referenced in 1 policies
Description
Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Zolgensma
Manufacturer
Novartis Gene Therapies, Inc.
HCPCS Dosage
Per tx dose (up to 5 x10^15 vg?)
Billing Units
1.0000
22
NDC Products
opps
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.